{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:28:53Z","timestamp":1786620533570,"version":"build-2736575974"},"posted":{"date-parts":[[2026,8,11]]},"group-title":"Oncology","reference-count":46,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"funder":[{"name":"National Cancer Institute","award":["U54CA274371"],"award-info":[{"award-number":["U54CA274371"]}]},{"name":"National Cancer Institute","award":["P50CA221707"],"award-info":[{"award-number":["P50CA221707"]}]},{"name":"National Cancer Institute","award":["U01CA239522"],"award-info":[{"award-number":["U01CA239522"]}]},{"name":"National Cancer Institute","award":["U01CA200468"],"award-info":[{"award-number":["U01CA200468"]}]},{"name":"National Cancer Institute","award":["R01CA299972"],"award-info":[{"award-number":["R01CA299972"]}]},{"name":"National Cancer Institute","award":["T32 CA217789"],"award-info":[{"award-number":["T32 CA217789"]}]},{"award":["RP210028"],"award-info":[{"award-number":["RP210028"]}],"id":[{"id":"https:\/\/ror.org\/0003xa228","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Pancreatic Cancer North America"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intraductal papillary mucinous neoplasms (IPMNs) are recognized as precursor lesions to pancreatic ductal adenocarcinoma (PDAC). However, the molecular programs underlying progression from low-grade dysplasia to advanced disease remain incompletely characterized. Herein, we performed an integrated plasma and tissue\u2013proteomic analyses coupled with spatial and single-cell transcriptomics to identify biologically coherent remodeling programs reflected in circulation that distinguish IPMN by dysplasia grade and invasive disease.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the O-link proximity extension assay platform, a panel of 1,104 proteins were quantified in plasma samples collected from patients with low-grade (LG) IPMN (n=30), high-grade (HG) IPMN with or without associated PDAC (IPMN\/PDAC; n=40) and PDAC without IPMN (n=8). Predictive performance of individual biomarkers were assessed; likelihood ratio testing was performed to identify protein biomarkers that were complementarity with CA19-9 for risk of malignancy of IPMN. Findings were intersected with available spatial (N= 13) and single-cell (N= 6) transcriptomic datasets of IPMN tissues as well as mass spectrometry-based proteomic profiles of an independent set of resected human IPMN tissues (N= 9).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 28, 43, and 35 circulating proteins were found to be differential in HG, IPMN\/PDAC, and HG + IPMN\/PDAC cases compared to LG IPMN. Among differential proteins were known PDAC-associated markers CEACAM5, CTRC, and REG3A as well as several biomarkers reflecting cytoskeletal and extracellular matrix remodeling and inflammatory processes. Focusing on cytoskeletal and ECM-related proteins and using likelihood ratio testing, an \u201cOR\u201d rule considering CA19-9, BGN, and ITGB1BP1 achieved overall sensitivity of 48.7% for HG + IPMN\/PDAC, including 38.1% sensitivity for HG IPMN, at an overall specificity of 90%, which was improved compared to that of CA19-9 alone (overall sensitivity of 28.2%; McNemar Exact test 1-sided p-value: 0.011). Integrated proteomic and spatial transcriptomic datasets of IPMN tissues revealed coordinated alterations cytoskeletal and ECM remodeling and elevated matrix stiffness as prominent features associated with IPMN\/PDAC, which paralleled concordant increases in BGN and ITGB1BP1. Cell-type of origin analyses based on spatial and single-cell data further revealed fibroblasts and myeloid cells as primary contributors to expression levels of BGN whereas ITGB1BP1 was primarily expressed in neoplastic epithelium.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Advanced IPMN dysplasia and invasive disease are characterized by coordinated tissue remodeling programs that are systemically reflected in circulating proteomic profiles. Blood-based biomarkers identified through our study, such as BGN and ITB1BP1, have potential to improve upon CA19-9 for risk stratification of IPMN to better guide clinical management.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.08.09.26360008","type":"posted-content","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:40:11Z","timestamp":1786444811000},"source":"Crossref","is-referenced-by-count":0,"title":["A blood-based signature of cytoskeletal and extracellular remodeling for risk stratification of intraductal papillary mucinous neoplasms"],"prefix":"10.64898","author":[{"given":"LaNisha","family":"Patterson","sequence":"first","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Ballar\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vilchis Celis","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxin","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Chellakkan Selvanesan","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Flores Villanueva","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Irajizad","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Koay","sequence":"additional","affiliation":[{"name":"Department of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Reinhart-King","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Rice University, Houston, Texas, 77005"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoa","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Max","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Hanash","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.","family":"Fahrmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026081303350815000_2026.08.09.26360008v1.1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.3340"},{"key":"2026081303350815000_2026.08.09.26360008v1.2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2232010815"},{"issue":"3","key":"2026081303350815000_2026.08.09.26360008v1.3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02784942","article-title":"Analysis of small cystic lesions of the pancreas","volume":"18","year":"1995","journal-title":"Int J Pancreatol"},{"issue":"4","key":"2026081303350815000_2026.08.09.26360008v1.4","first-page":"395","article-title":"Pancreatic cystic tumours: when to resect, when to observe","volume":"14","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026081303350815000_2026.08.09.26360008v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.10.001"},{"key":"2026081303350815000_2026.08.09.26360008v1.6","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000155055.14238.25"},{"key":"2026081303350815000_2026.08.09.26360008v1.7","doi-asserted-by":"crossref","unstructured":"Tanaka, M. , et al., International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology, 2012. 12(3): p. 183-97.","DOI":"10.1016\/j.pan.2012.04.004"},{"key":"2026081303350815000_2026.08.09.26360008v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.04.005"},{"key":"2026081303350815000_2026.08.09.26360008v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9491"},{"key":"2026081303350815000_2026.08.09.26360008v1.10","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000217673.04165.ea"},{"issue":"7","key":"2026081303350815000_2026.08.09.26360008v1.11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1477-2574.2010.00216.x","article-title":"Pancreatectomy risk calculator: an ACS-NSQIP resource","volume":"12","year":"2010","journal-title":"HPB (Oxford"},{"key":"2026081303350815000_2026.08.09.26360008v1.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335220"},{"key":"2026081303350815000_2026.08.09.26360008v1.13","doi-asserted-by":"crossref","first-page":"217537","DOI":"10.1016\/j.canlet.2025.217537","article-title":"Elevated levels of circulating microbial-associated uremic toxins are associated with metastatic duodenopancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia Type 1","volume":"614","year":"2025","journal-title":"Cancer Lett"},{"key":"2026081303350815000_2026.08.09.26360008v1.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192"},{"key":"2026081303350815000_2026.08.09.26360008v1.15","doi-asserted-by":"crossref","unstructured":"Sans, M. , et al., Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential. Cancer Discov, 2023.","DOI":"10.1158\/2159-8290.c.6753887.v2"},{"key":"2026081303350815000_2026.08.09.26360008v1.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-1200"},{"issue":"12","key":"2026081303350815000_2026.08.09.26360008v1.17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1158\/1078-0432.CCR-24-2931","article-title":"Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression","volume":"31","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026081303350815000_2026.08.09.26360008v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.54"},{"key":"2026081303350815000_2026.08.09.26360008v1.19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751311"},{"key":"2026081303350815000_2026.08.09.26360008v1.20","doi-asserted-by":"crossref","unstructured":"20. Ahmad, S.M.S. , et al., ITGB1BP1, a Novel Transcriptional Target of CD44-Downstream Signaling Promoting Cancer Cell Invasion. Breast Cancer (Dove Med Press), 2023. 15: p. 373-380.","DOI":"10.2147\/BCTT.S404565"},{"key":"2026081303350815000_2026.08.09.26360008v1.21","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.200139"},{"key":"2026081303350815000_2026.08.09.26360008v1.22","doi-asserted-by":"crossref","first-page":"852016","DOI":"10.3389\/fcell.2022.852016","article-title":"Paxillin: A Hub for Mechano-Transduction from the \u03b23 Integrin-Talin-Kindlin Axis","volume":"10","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026081303350815000_2026.08.09.26360008v1.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1955"},{"key":"2026081303350815000_2026.08.09.26360008v1.24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12157-0"},{"key":"2026081303350815000_2026.08.09.26360008v1.25","doi-asserted-by":"crossref","first-page":"102714","DOI":"10.1016\/j.ebiom.2020.102714","article-title":"Evolution of the immune landscape during progression of pancreatic intraductal papillary mucinous neoplasms to invasive cancer","volume":"54","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"2026081303350815000_2026.08.09.26360008v1.26","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.surg.2018.07.014","article-title":"Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?","volume":"164","year":"2018","journal-title":"Surgery"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3892\/br.2014.376","article-title":"Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis","volume":"3","year":"2015","journal-title":"Biomed Rep"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hpb.2023.09.001","article-title":"Pancreatectomy for intraductal papillary mucinous neoplasm: has anything changed in North America?","volume":"26","year":"2024","journal-title":"HPB (Oxford"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.29","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1038\/s41598-025-00517-1","article-title":"Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma","volume":"15","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.30","doi-asserted-by":"crossref","first-page":"e70187","DOI":"10.1002\/ueg2.70187","article-title":"Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer","volume":"14","year":"2026","journal-title":"United European Gastroenterol J"},{"issue":"9","key":"2026081303350815000_2026.08.09.26360008v1.31","doi-asserted-by":"crossref","first-page":"110782","DOI":"10.1016\/j.isci.2024.110782","article-title":"KRT19 is regulated by miR-642a-5p and promotes pancreatic cancer progression through the Wnt\/beta-catenin pathway","volume":"27","year":"2024","journal-title":"iScience"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12964-025-02103-4","article-title":"REG3A secreted by peritumoral acinar cells enhances pancreatic ductal adenocarcinoma progression via activation of EGFR signaling","volume":"23","year":"2025","journal-title":"Cell Commun Signal"},{"key":"2026081303350815000_2026.08.09.26360008v1.33","doi-asserted-by":"crossref","unstructured":"Ungefroren, H. , et al., RAC1b Collaborates with TAp73alpha-SMAD4 Signaling to Induce Biglycan Expression and Inhibit Basal and TGF-beta-Driven Cell Motility in Human Pancreatic Cancer. Biomedicines, 2024. 12(1).","DOI":"10.3390\/biomedicines12010199"},{"key":"2026081303350815000_2026.08.09.26360008v1.34","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.138.5.1149"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1756-9966-31-68","article-title":"Molecular markers associated with outcome and metastasis in human pancreatic cancer","volume":"31","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5152\/tjg.2024.21430","article-title":"Gene Expression Array Analyses Predict Proto-Oncogene Expression During Perineural Invasion in Pancreatic Ductal Adenocarcinoma","volume":"35","year":"2024","journal-title":"Turk J Gastroenterol"},{"key":"2026081303350815000_2026.08.09.26360008v1.37","doi-asserted-by":"crossref","unstructured":"Knipper, K. , et al., Cancer-Associated Fibroblast Heterogeneity and Its Influence on the Extracellular Matrix and the Tumor Microenvironment. Int J Mol Sci, 2023. 24(17).","DOI":"10.3390\/ijms241713482"},{"key":"2026081303350815000_2026.08.09.26360008v1.38","doi-asserted-by":"publisher","DOI":"10.1369\/0022155412456380"},{"key":"2026081303350815000_2026.08.09.26360008v1.39","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-021-04216-z"},{"key":"2026081303350815000_2026.08.09.26360008v1.40","doi-asserted-by":"crossref","unstructured":"Berdiaki, A. , et al., The Landscape of Small Leucine-Rich Proteoglycan Impact on Cancer Pathogenesis with a Focus on Biglycan and Lumican. Cancers (Basel), 2023. 15(14).","DOI":"10.3390\/cancers15143549"},{"issue":"1","key":"2026081303350815000_2026.08.09.26360008v1.41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1515\/jtim-2025-0008","article-title":"Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models","volume":"13","year":"2025","journal-title":"J Transl Int Med"},{"key":"2026081303350815000_2026.08.09.26360008v1.42","doi-asserted-by":"crossref","unstructured":"Zhu, S. , et al., MiR-548an, Transcriptionally Downregulated by HIF1alpha\/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression. Mol Cancer Ther, 2016. 15(9): p. 2209-19.","DOI":"10.1158\/1535-7163.MCT-15-0877"},{"key":"2026081303350815000_2026.08.09.26360008v1.43","first-page":"1742644","article-title":"Vimentin expression as a prognostic marker in pancreatic cancer: a systematic review and meta-analysis","volume":"13","year":"2026","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"2026081303350815000_2026.08.09.26360008v1.44","doi-asserted-by":"crossref","first-page":"e0346011","DOI":"10.1371\/journal.pone.0346011","article-title":"CAPG serves as a prognostic biomarker and promotes proliferation and migration in pancreatic ductal adenocarcinoma","volume":"21","year":"2026","journal-title":"PLoS One"},{"key":"2026081303350815000_2026.08.09.26360008v1.45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M211258200"},{"key":"2026081303350815000_2026.08.09.26360008v1.46","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21215"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.08.09.26360008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:35:18Z","timestamp":1786617318000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.08.09.26360008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":46,"URL":"https:\/\/doi.org\/10.64898\/2026.08.09.26360008","relation":{},"subject":[],"published":{"date-parts":[[2026,8,11]]},"subtype":"preprint"}}